FY2026 EPS Estimates for Avanos Medical Decreased by Analyst

Avanos Medical, Inc. (NYSE:AVNS) – Stock analysts at Zacks Research dropped their FY2026 earnings per share (EPS) estimates for Avanos Medical in a research report issued on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.99 for the year, down from their prior estimate of $2.00. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share.

Separately, StockNews.com lowered shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Trading Down 1.8 %

Shares of Avanos Medical stock opened at $15.55 on Friday. The stock has a market cap of $714.63 million, a PE ratio of 45.74 and a beta of 0.95. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The company has a 50-day moving average of $18.33 and a two-hundred day moving average of $21.04. Avanos Medical has a 12-month low of $15.51 and a 12-month high of $25.36.

Institutional Trading of Avanos Medical

Several institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its position in shares of Avanos Medical by 6.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company’s stock valued at $1,672,000 after acquiring an additional 4,472 shares in the last quarter. Geode Capital Management LLC grew its stake in Avanos Medical by 1.5% in the third quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock valued at $25,337,000 after purchasing an additional 16,065 shares in the last quarter. Barclays PLC increased its position in Avanos Medical by 446.2% in the 3rd quarter. Barclays PLC now owns 96,194 shares of the company’s stock worth $2,311,000 after purchasing an additional 78,583 shares during the last quarter. Zacks Investment Management purchased a new stake in shares of Avanos Medical during the 3rd quarter worth about $335,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Avanos Medical during the 3rd quarter valued at about $212,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.